High-throughput screening techniques are being used to identify the next generation of improved CAR constructs for tumor cell targeting.
Precision control and persistence. Despite success in hematological malignancies, existing cell therapies have struggled to address solid tumors and still carry risks of toxic immune responses. To address these concerns, start-ups continue to improve the binding specificity and persistence of cell therapies, powered by more than $450 million in funding in 2022. High-throughput screening techniques are being used to identify the next generation of improved CAR constructs for tumor cell targeting. Synthetic receptors and biological logic gates (that is, biological circuits designed from components such as proteins) are being tested to help cell therapies evade immunosuppressive signals in the tumor microenvironment.